A Phase III Randomized Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion (ECOG 1208)
Conditions
Liver Cancer
What is the purpose of this trial?
Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Both
Click here for detailed information about who can participate in this trial.
- Sponsor:
- National Cancer Institute (NCI)
- Dates:
- April 2011
- Last Updated:
- Study HIC#:
- 1102008042
Clinicaltrials.gov ID: Yale5024181
For more information about this trial, contact:
Investigator
Stacey Stein, MMS, MD
Principal Investigator
